It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

After dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative ...

Earlier this week, I also pulled the trigger on shares of specialty biotech company BioMarin Pharmaceutical (NASDAQ: BMRN).

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced the appointment of Jeff Ajer to its board of directors. Ajer, who most recently served as the Chief Commercial Officer at BioMarin ...

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...